Authored by
Dr. Nikhil Taxak, Ph. D, APAC Head, Pricing and Market Access Data and Analytics, Access Infinity.
The first half of 2025 has underscored a decisive shift in global market access and pricing as evident from the payers doubling down on cost-containment levers, tightening HTA frameworks, and tying pricing to industrial and supply resilience goals. For pharma, the year is shaping up as a balancing act, navigating downward price pressure while adapting evidence strategies to meet evolving payer demands. Looking ahead, the second half of 2025 and beyond will test pharmaceutical manufacturers’ ability to be more agile, evidence-led, and globally coordinated as policies converge on value, sustainability, and equitable access.
Cost-Containment & Pricing Pressure: The Race Is On
HTA Reforms & Innovation Incentives: Value, Value, Value!
Access & Transparency: The Next Frontier
Adaptations to Regulatory/HTA Frameworks – Streamlined Timelines!
2025 so far has not been business as usual. It is the year payers reset evidence standards and tie pricing and market access to commercial strategy. The winners? Teams that move early, evidence-first, locally aligned and who quickly adapt to these dynamically evolving global payer policies.
Click here to learn about Access Infinity’s Digital + Consulting Suite of Solutions
About the author
Nikhil leads the Data and Analytics team with more than 12 years of experience in global pricing and market access (P&MA). He has extensive P&MA experience in both consulting and pharma industry (including Novartis Oncology) across therapy areas and global markets. He is responsible for driving strategy and roadmap for Access Hub, NURO and evidence Hub while ensuring data quality, accuracy, and depth.
Don’t let your access and pricing strategy fall behind! Click to subscribe and unlock details and expert commentary on each key policy shift from 2025’s ever-evolving payer landscape.
Contact Nikhil at nikhil@accessinfinity.com
